Testosterone Enanthate and Imaging Contrast Dye: What Patients and Clinicians Need to Know

Is There a Direct Drug-Drug Interaction Between Testosterone Enanthate and Contrast Agents?

No direct drug-drug interaction between testosterone enanthate and either iodinated or gadolinium-based contrast media has been identified in pharmacokinetic studies or FDA product labeling. Testosterone enanthate is hydrolyzed to free testosterone after intramuscular injection, and its metabolism is hepatic via CYP3A4 and glucuronidation pathways. Contrast agents are renally excreted, inert, and do not share those metabolic routes.

The FDA prescribing information for testosterone enanthate (NDA 008580) lists anticoagulants, insulin, and corticosteroids as drugs with clinically meaningful interactions, but contrast media are not mentioned. [1]

That absence of a direct interaction does not mean imaging is without considerations for patients on TRT. The indirect effects discussed in the sections below carry real clinical weight.

Why Indirect Effects Still Matter

Testosterone enanthate reliably raises hematocrit. A 2017 analysis of 14 randomized trials published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy increased hemoglobin by a mean of 0.93 g/dL and hematocrit by roughly 3.2 percentage points compared to placebo across doses and formulations. [2] In some patients, especially those using higher doses or who are older, hematocrit can exceed 54%, the threshold at which the Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends dose reduction or phlebotomy. [3]

That degree of erythrocytosis matters during contrast procedures because contrast-related vasodilation, fluid shifts, and the procedure environment itself can amplify thrombotic risk in blood with abnormally high viscosity.

Iodinated Contrast and Testosterone Enanthate: Specific Considerations

Iodinated contrast agents (ICAs) are used in CT scans, angiography, and fluoroscopic procedures. They are classified as either high-osmolality (e.g., diatrizoate) or low-osmolality/iso-osmolality agents (e.g., iohexol, iodixanol).

Renal Safety and eGFR Thresholds

The primary safety concern with ICAs is contrast-induced acute kidney injury (CI-AKI). The ACR Manual on Contrast Media (2023 edition) defines elevated risk at eGFR <30 mL/min for intravenous ICAs and recommends individualized assessment between eGFR 30 to 44 mL/min. [4]

Testosterone enanthate does not directly injure the kidneys, but it can cause secondary effects on renal function through erythrocytosis-related hyperviscosity and, at high doses, by promoting sodium and water retention. A 2021 pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) identified a small but non-trivial signal for renal and urinary disorders in testosterone users, though causality was not established. Patients on TRT who have concurrent hypertension, diabetes, or metabolic syndrome face compounded CI-AKI risk. [5]

Practical guidance: obtain a current eGFR (within 90 days, or more recently if the patient's condition is changing) before elective contrast CT in any patient on testosterone enanthate, particularly those with cardiometabolic comorbidities.

Thyroid Iodine Uptake Suppression

Iodinated contrast media release free iodide, which can suppress radioactive iodine uptake in the thyroid for 4 to 8 weeks post-administration. This is relevant for patients who need thyroid scintigraphy or radioactive iodine therapy scheduled close to a contrast CT.

Testosterone weakly suppresses thyroid-binding globulin (TBG), resulting in slightly lower total T4 and T3 levels with preserved free hormone concentrations. [6] This TBG effect does not amplify the iodine suppression from contrast, but clinicians interpreting post-contrast thyroid function tests should recognize that testosterone independently shifts TBG-dependent assays. A patient on TRT with a low total T4 is not automatically hypothyroid; free T4 and TSH remain the appropriate assessments.

Metformin Consideration (Common Co-prescription)

Many men on TRT for metabolic indications also take metformin. The ACR recommends holding metformin for 48 hours after iodinated contrast in patients with eGFR <60 mL/min due to lactic acidosis risk. [4] Prescribers managing a patient on both testosterone enanthate and metformin should flag this co-prescription in the imaging pre-procedure checklist.

Gadolinium-Based Contrast Agents and Testosterone Enanthate

Gadolinium-based contrast agents (GBCAs) are used in MRI. Nine agents are approved by the FDA; they are classified by molecular structure (linear vs. Macrocyclic) and protein binding (ionic vs. Non-ionic).

Nephrogenic Systemic Fibrosis Risk

Nephrogenic systemic fibrosis (NSF) is the most serious risk associated with GBCAs. The FDA issued a boxed warning for all GBCAs regarding NSF in patients with acute kidney injury or chronic kidney disease with eGFR <30 mL/min. [7] In those patients, Group I agents (gadodiamide, gadoversetamide, gadopentetate dimeglumine) are contraindicated; Group II and Group III agents may be used with caution.

The connection to testosterone enanthate, again, is indirect. Polycythemia secondary to TRT can shift the apparent creatinine-based eGFR. Elevated muscle mass in men on androgens can raise serum creatinine without proportional decreases in actual glomerular filtration, leading to a potential overestimation of renal function by creatinine-based equations. Cystatin C-based eGFR is more reliable in this population and should be considered before GBCA administration in patients with borderline renal function. [8]

Gadolinium Retention

Trace gadolinium deposition in brain tissue has been observed on MRI in patients receiving multiple GBCA administrations, regardless of renal function. The FDA updated GBCA labeling in 2017 to note this finding, though no adverse clinical effects from deposition have been established to date. [9] Testosterone enanthate has no known effect on gadolinium retention or clearance.

Hematocrit, Polycythemia, and Contrast Procedure Safety

This is the most clinically significant indirect concern linking testosterone enanthate and imaging contrast procedures.

How TRT Raises Hematocrit

Testosterone stimulates erythropoiesis primarily through two mechanisms: direct androgen receptor stimulation of erythroid progenitor cells in bone marrow, and indirect suppression of hepcidin, which increases iron availability for red cell production. [10] The effect is dose-dependent. Men receiving 200 mg every 2 weeks show greater hematocrit elevation than those on 100 mg every 2 weeks or low-dose weekly protocols.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone therapy was associated with a higher incidence of hematocrit exceeding 54% compared to placebo (incidence rate 5.7% vs. 1.5%). TRAVERSE did not find an increase in major adverse cardiovascular events (MACE) at 4-year follow-up, but it did confirm that polycythemia is a real and common adverse effect of TRT. [11]

Procedural Thrombosis Risk

Hyperviscosity from erythrocytosis increases the theoretical risk of thrombus formation in catheterized vessels or around contrast injection sites during invasive contrast procedures (e.g., cardiac catheterization, interventional radiology). No large RCT has quantified this risk specifically in TRT patients undergoing contrast procedures. Current guidance from the Society of Interventional Radiology and ACR does not single out TRT as a contraindication, but proceduralists should be aware of a patient's current hematocrit.

Pre-Imaging Hematocrit Decision Framework for Patients on Testosterone Enanthate:

| Hematocrit | Recommended Action Before Contrast Procedure | |---|---| | <50% | Proceed per standard ACR contrast protocol | | 50 to 53% | Note in procedure record; ensure adequate hydration; discuss with ordering clinician | | 54 to 56% | Consider phlebotomy per Endocrine Society guideline before elective procedure; discuss with TRT prescriber | | >56% | Hold elective contrast imaging; mandatory TRT dose reduction or phlebotomy before proceeding |

This framework integrates ACR contrast safety thresholds with the Endocrine Society 2018 TRT guideline hematocrit action points. It is not a replacement for individualized clinical judgment.

Anticoagulation Interactions Amplified by Contrast Procedures

Testosterone enanthate has a well-documented pharmacodynamic interaction with warfarin. The FDA label and multiple case reports note that androgens potentiate the anticoagulant effect of coumarin derivatives, potentially reducing the warfarin dose requirement by 20 to 30%. [1] Patients on warfarin require more frequent INR monitoring when testosterone therapy is started, stopped, or dose-adjusted.

This matters for imaging because some contrast procedures require anticoagulation hold or reversal (e.g., renal biopsy under CT guidance, embolization procedures). A patient on both testosterone enanthate and warfarin may have an unexpectedly supratherapeutic INR heading into a procedure. INR should be checked within 7 days before any invasive contrast procedure in this population.

The Endocrine Society's 2018 guideline states: "Clinicians should be aware that testosterone therapy potentiates the action of anticoagulants and this interaction can result in clinically significant bleeding." [3]

Alcohol Use on Testosterone Enanthate: A Brief Note

Alcohol does not interact pharmacokinetically with testosterone enanthate in a clinically significant way at moderate intake levels. However, chronic heavy alcohol use suppresses endogenous testosterone through multiple mechanisms: hypothalamic-pituitary-gonadal axis suppression, direct Leydig cell toxicity, and increased aromatization of testosterone to estradiol in adipose tissue. [12]

For patients on TRT, heavy alcohol use can undermine treatment goals and complicate metabolic monitoring. The 2022 NIAAA guidelines define heavy drinking as more than 14 standard drinks per week for men. Patients should be counseled accordingly. No alcohol hold is required before testosterone enanthate injections.

Monitoring Checklist Before Contrast-Enhanced Imaging in TRT Patients

Clinicians ordering imaging for patients on testosterone enanthate should confirm the following before the procedure.

Laboratory Parameters

• Hematocrit/hemoglobin: current within 90 days. Hold elective contrast imaging if hematocrit exceeds 54% until addressed per Endocrine Society guidance.
• eGFR: current within 90 days. Use cystatin C-based eGFR if creatinine-based result is borderline, given the muscle-mass confound in androgen users.
• INR/PT: if the patient is on warfarin or another vitamin K antagonist, check within 7 days pre-procedure.
• TSH/free T4: if post-contrast thyroid imaging or RAI therapy is planned within 8 weeks.

Medication Review

• Confirm current testosterone enanthate dose and injection frequency.
• Screen for concurrent metformin, warfarin, insulin, or corticosteroids.
• Review blood pressure medications; testosterone can reduce the efficacy of some antihypertensives through sodium retention.

Hydration

Standard pre-procedure hydration protocols apply. Patients with elevated hematocrit benefit from oral hydration beginning 24 hours before the contrast study.

What to Tell Your Imaging Team

Patients on testosterone enanthate should disclose their TRT at every pre-procedure intake, even if they consider it a supplement or wellness medication rather than a prescription drug. The imaging team needs this information to:

1. Check the current hematocrit and flag values above 50%.
2. Assess renal function using the correct eGFR formula.
3. Identify co-prescriptions (warfarin, metformin) that carry procedure-specific protocols.

A simple statement works: "I take testosterone enanthate injections. My last dose was [date] and my dose is [amount] mg."

No dose adjustment of testosterone enanthate is needed before or after contrast-enhanced imaging.

Summary of Interaction Classification

The interaction between testosterone enanthate and imaging contrast agents falls into two categories:

No interaction (direct): Testosterone enanthate and iodinated or gadolinium-based contrast media do not share metabolic pathways, plasma protein binding sites, or excretion routes. No pharmacokinetic interaction has been identified.

Indirect clinical considerations (real, manageable): Testosterone-related polycythemia, renal function changes, TBG suppression, and the warfarin potentiation interaction all require pre-imaging assessment. These are not reasons to avoid contrast imaging; they are reasons to review labs before proceeding.

The ACR Manual on Contrast Media (2023) provides the governing framework for all contrast decisions in the United States, and it does not list androgen therapy as a contraindication to either ICAs or GBCAs. [4] Individualized pre-procedure assessment guided by current hematocrit and eGFR values is the standard of care.